Elucid

Elucid is a medical technology company based in Boston that has developed PlaqueIQ, an AI-powered software platform for analyzing cardiovascular disease. The software provides non-invasive characterization of arterial plaque composition and morphology from CT angiography scans. It is the only FDA-cleared tool that can quantify plaque features like lipid-rich necrotic core, calcification, and fibrous cap thickness by leveraging machine learning algorithms trained on thousands of tissue samples.

PlaqueIQ aims to improve diagnosis and treatment of heart disease by enabling physicians to objectively evaluate plaque stability and rupture risk, key drivers of myocardial infarction and ischemic stroke events. Validated in clinical studies, the technology demonstrates superior accuracy compared to traditional visual assessment methods in predicting adverse cardiac events and stroke risk. Elucid's software provides insights into early-stage atherosclerosis development, allowing preventative care pathways before onset of symptoms.

Beyond plaque analysis, Elucid is also developing techniques to non-invasively measure fractional flow reserve and ischemia based on its PlaqueIQ algorithms. This proprietary approach could offer a comprehensive solution for coronary artery disease evaluation from a single CT scan.

The company raised USD 80 million in Series C funding in November 2023, bringing its total capital raised to USD 121 million. Elucid plans to use the investment to accelerate commercial expansion of its cardiac imaging analysis suite and broaden clinical research efforts.